Document is current
Any future updates will be listed below
-
Authors
Tominaga, Masahiro https://orcid.org/0000-0001-9691-0428
Shima, Yoko
Nozaki, Kenta https://orcid.org/0000-0002-0409-3000
Ito, Yoichiro
Someda, Masataka
Shoya, Yuji
Hashii, Noritaka https://orcid.org/0000-0003-1363-2050
Obata, Chihiro
Matsumoto-Kitano, Miho
Suematsu, Kohei
Matsukawa, Tadashi
Hosoya, Keita
Hashiba, Noriko https://orcid.org/0000-0002-2753-6708
Kondo, Akihiko https://orcid.org/0000-0003-1527-5288
Ishii, Jun https://orcid.org/0000-0003-2568-515X
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP21ae0121002, JP21ae0121005, JP21ae0121006, JP21ae0121007, JP20ae0101055, and JP20ae0101060)
MEXT | Japan Science and Technology Agency (JPMJCR21N2, JPMJGX23B4)
MEXT | Japan Society for the Promotion of Science (JP18K14374)
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 21 November 2024
First Online: 19 December 2024
Competing interests
: M.S. and Y.Shoya are employees of Pharma Foods International Co. Ltd. M.T., K.N., A.K., and J.I. are inventors of pending patent applications submitted by Kobe University that cover the inducible synthetic promoters described in this study (PCT/JP2021/044573, PCT/JP2021/044574, and JP2020202234). Y.I. is the inventor of one of the above pending patent applications (PCT/JP2021/044573). M.T., Y.I., M.M.-K., M.S., Y.Shoya., A.K., and J.I. are inventors of the pending patent application submitted by Kobe University and Pharma Foods International Co. Ltd. that covers the IgY antibody obtained in this study (JP2023188697). The other authors declare no competing interests.
